Abstract
Management of patients with coronary artery disease (CAD) includes the use of drug therapy, endovascular
and surgical methods of treatment. Myocardial revascularization improvement, advances in techniques and
equipment have established an initial management strategy of revascularization as safe and effective in
patients with CAD. Despite this according to several randomized trials the question of initial management
strategy of optimal medical therapy (OMT) alone in stable ischemic heart disease (SIHD) still remains open.
An important issue to resolve is the use of OMT in patients with coronary artery disease after myocardial
revascularization to improve surgical treatment prognosis. Poor awareness of physicians in many aspects of
evidence-based pharmacological therapy and lack of patient education, low patient treatment compliance
may influence the effectiveness of pharmacological and surgical treatment.
The review is devoted to modern aspects of optimal medical therapy in patients with coronary artery disease
after myocardial revascularization to improve the results of surgical treatment.
References
- Сердечно-сосудистые заболевания. Информационный
бюллетень. 2013: 317.
- Сайт Федеральной службы государственной
статистики. Available at: http://www.gks.ru/.
- Бокерия О.Л., Биниашвили М.Б. Внезапная сердечная
смерть и ишемическая болезнь сердца.
Анналы аритмологии. 2013; 2: 69—79.
- Kiselev A.R., Gridnev V.I., Prokhorov M.D.,
Karavaev A.S., Posnenkova O.M., Ponomarenko V.I.
et al. Evaluation of 5-year risk of cardiovascular
events in patients after acute myocardial infarction
using synchronization of 0.1-Hz rhythms in cardiovascular
system. Ann. Noninvasive Electrocardiol.
2012; 17 (3): 204—13.
- Бокерия Л.А., Никонов С.Ф., Бенделиани Н.Г., Че-
ишвили З.М., Крымов К.В. Эффективность и влияние
многофакторного подхода к лечению больных
ишемической болезнью сердца после изолированного
коронарного шунтирования и его
сочетания с геометрической реконструкцией левого
желудочка на качество жизни и потребность
в госпитализациях (результаты 12-месячного
рандомизированного клинического исследования).
Анналы аритмологии. 2011; 4: 43—53.
- Посненкова О.М., Киселев А.Р., Шварц В.А. Влияние
терапии препаратом кардионат на качество
жизни у больных острым инфарктом миокарда
с подъемом сегмента ST в раннем пост-
инфарктном периоде. Consilium Medicum. 2010;
5: 94-8.
- Киселев А.Р., Гриднев В.И., Караваев А.С., По-
сненкова О.М., Пономаренко В.И., Прохоров М.Д.
и др. Оценка пятилетнего риска летального исхода
и развития сердечно-сосудистых событий
у пациентов с острым инфарктом миокарда на
основе синхронизации 0,1 Гц-ритмов в сердечно-
сосудистой системе. Саратовский научномедицинский
журнал. 2010; 2: 328-38.
- Practice Guidelines 2012 ACCF/AHA/ACP/
AATS/PCNA/SCAI/STS. Guideline for the
Diagnosis and Management of Patients With Stable
Ischemic Heart Disease. A Report of the American
College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines, and
the American College of Physicians, American
Association for Thoracic Surgery, Preventive
Cardiovascular Nurses Association, Society for
Cardiovascular Angiography and Interventions, and
Society of Thoracic Surgeon. Circulation. 2012; 126:
e354-471.
- Бокерия Л.А., Бокерия О.Л., Кудзоева З.Ф. Сравнительный
анализ применения коронарной ангиопластики
и операции аортокоронарного шунтирования
у пациентов со стабильной стенокардией:
история вопроса и современное состояние
проблемы. Анналы хирургии. 2009; 6: 10-23.
- Бокерия Л.А., Бокерия О.Л., Кудзоева З.Ф. Коронарная
ангиопластика и операция аортокоронарного
шунтирования у пациентов со стабильной
стенокардией: сравнительный анализ результатов.
Сердечно-сосудистая хирургия:
информационный сборник. 2010; 3: 3-25.
- Бокерия Л.А., Беришвили И.И., Вахромеева М.Н.,
Старостин М.В., Хвичия Л.Э., Глушкова И.В. и
др. 700 операций трансмиокардиальной лазерной
реваскуляризации (ТМЛР). Результаты
многолетнего применения ТМЛР Анналы хирургии.
2011; 3: 56-8.
- Mehta S.R., Cannon C.P., Fox K.A., Wallentin L.,
Boden W.E., Spacek R. et al. Routine vs selective
invasive strategies in patients with acute coronary
syndromes: a collaborative meta-analysis of randomized
trials. JAMA. 2013; 293: 2908-17.
- Frye R.L., August P., Brooks M.M., Hardison R.M.,
Kelsey S.F., MacGregor J.M. et al. A randomized
trial of therapies for type 2 diabetes and coronary
artery disease. N. Engl. J. Med. 2009; 360: 2503-15.
- Shaw L.J., Berman D.S., Maron D.J., Mancini G.B.,
Hayes S.W., Hartigan P.M. et al. Optimal medical
therapy with or without percutaneous coronary
intervention to reduce ischemic burden: results
from the Clinical Outcomes Utilizing Revascularization
and AGgressive drug Evaluation
(COURAGE) trial nuclear substudy. Circulation.
2008; 117: 1283-91.
- Serruys P. SYNTAX 4-year Outcomes in the LM
Subgroup. In: TCT; San Francisko; 2011.
- Chan P.S., Patel M.R., Klein L.W., Patel M.R.,
Krone R.J., Dehmer G.J. et al. Appropriateness of
percutaneous coronary intervention. JAMA. 2011;
306: 53-61.
- Yusuf S., Zucker D., Peduzzi P., Fisher L.D.,
Takaro T., Kennedy J.W. et al. Effect of coronary
artery bypass graft surgery on survival: overview
of 10-year results from randomised trials by the
Coronary Artery Bypass Graft Surgery Trialists
Collaboration. Lancet. 1994; 344 (8922):
563-70.
- Bucher H.C., Hengstler P., Schindler C., Guyatt G.H.
Percutaneous transluminal coronary angioplasty
versus medical treatment for non-acute coronary
heart disease: meta-analysis of randomised control
trials. BMJ. 2000; 321: 73-7.
- ISHEMIA trial. Available at https://ischemiatrial.
org/.
- Daly C.A., Clemens F., Sendon J.L., Tavazzi L.,
Boersma E., Danchin N. et al. The initial management
of stable angina in Europe, from the Euro
Heart Survey: a description of pharmacological
management and revascularization strategies initiated
within the first month of presentation to a cardiologist
in the Euro Heart Survey of Stable Angina.
Eur. Heart J. 2005; (26): 1011-22.
- Antithrombotic Trialists' Collaboration. Collaborative
meta-analysis of randomised trials of
antiplatelet therapy for prevention of death,
myocardial infarction, and stroke in high risk
patients. BMJ. 2002; 324 (7329): 71-86.
- Mega J.L., Simon T., Collet J.Ph, Anderson J.L.,
Antman E.M. Reduced-function CYP2C19 genotype
and risk of adverse clinical outcomes among
patients treated with clopidogrel predominantly for
PCI a meta-analysis. JAMA. 2011; 306 (11):
1215-23.
- Holmes M.V., Perel P., Shah T., Hingorani A.D.,
Casas J.P. CYP2C19 genotype, clopidogrel
metabolism, platelet function, and cardiovascular
events: a systematic review and meta-analysis.
JAMA. 2011; 306 (24): 2704-14.
- Mega J.L., Simon T. Collet J.P., Anderson J.L.,
Antman E.M., Bliden K. et al. Reduced-function
CYP2C19 genotype and risk of adverse clinical outcomes
among patients treated with clopidogrel predominantly
for PCI: a meta-analysis. JAMA. 2010;
304 (16): 1821-30.
- Bhatt D.L., Cryer B.L., Contant C.F., Cohen M.,
Lanas A., Schnitzer T.J. et al. Clopidogrel with or
without omeprazole in coronary artery disease. N.
Engl. J. Med. 2010; 363 (20): 1909-17.
- Wiviott S.D., Braunwald E., McCabe C.H.,
Montalescot G., Ruzyllo W., Gottlieb S. et al. for
the TRITON-TIMI 38 Investigators. Prasugrel
versus Clopidogrel in Patients with Acute
Coronary Syndromes. N. Engl. J. Med. 2007; 357:
2001-15.
- Serebruany V.L. The TRITON versus PLATO trials:
Differences beyond platelet inhibition. Thromb.
Haemost. 2010; 103 (2): 1-3.
- Gurbel P.A., Bliden K.P., Butler K., Antonino M.J.,
Wei C., Teng R. et al. Response to ticagrelor in
clopidogrel nonresponders and responders and the
effect of switching therapies: The RESPOND study
Circulation. 2010; 121: 1188-99.
- Bhatt D.L., Lincoff A.M., Gibson C.M., Stone G.W.,
McNulty S., Montalescot G. et al. Intravenous
platelet blockade with cangrelor during PCI. N.
Engl. J. Med. 2009; 361 (24): 2330-41.
- Henerici M.G. Rationale and desain of the prevention
and cardiovascular events of ischemic origin
with terutroban in patients with a history of
ischemic stroke or transient ischemic stroke or transient
ischemic attack (PERFORM) study.
Cerebrovasc. Disease. 2009 (Suppl. 3): 28-32.
- Brown D.L., Fann C.S., Chang C.J. Meta-analysis of
effectiveness and safety of abciximab versus eptifibatide
or tirofiban in percutaneous coronary intervention.
Am. J. Cardiol. 2001; 87 (5): 537-41.
- Goto S., Ogawa H., Takeuchi M. Flather M.D.,
Bhatt D.L. Double-blind, placebo-controlled Phase
II studies of the protease-activated 1 antagonist
E5555 (atopaxar) in Japanese patients with acute
coronary syndrome or high-risk coronary disease.
Eur. Heart J. 2010; 31: 2601-13.
- O'Donoghue M.L., Bhatt D.L., Wiviott S.D. Safety
and tolerability of atopaxar in the treatment of
patients with acute coronary syndromes: the lessons
from antagonizing the cellular effect of thrombin
coronary artery disease trial. Circulation. 2011; 123
(17): 1843-53.
- Merck says additional information provided to investigators
in clinical study of vorapaxar [press release];
2011. Available at: http://www.pcronline.com/
News/Press-releases-archives/Merck-Says-
Additional-Information-Provided-to-Investigators-
in-Clinical-Study-of-Vorapaxar.
- Pedersen T.R. Coronary artery disease: the
Scandinavian Simvastatin Survival Study
Experience. Am. J. Cardiol. 1998; 82: 53-6.
- Киселев А.Р., Шварц В.А. Розувастатин: итоги и
перспективы. Русский медицинский журнал.
2013; 21 (5): 274-6.
- БритовА.Н., Чурина М.П.Клиническая, липид-
нормализующая и плейотропная эффективность
розувастатина; обзор серии исследований
GALAXY Кардиоваскулярная терапия и профилактика.
2011; 10 (1): 104-9.
- Briguori C., Visconti G., Focaccio A., Golia B.,
Chieffo A., Castelli A. et al. Novel approaches for
preventing or limiting events (Naples) II trial:
impact of a single high loading dose of atorvastatin
on periprocedural myocardial infarction. J. Am.
Coll. Cardiol. 2009; 54 (23): 2157-63.
- Tian J., Gu X., Sun Y., Ban X., Xiao Y., Hu S., Yu B.
Effect of statin therapy on the progression of coronary
atherosclerosis. BMC Cardiovasc. Disorders.
2012; 1: 12-70.
- Di Sciascio G. The ARMYDA trials (Atorvastatin for
Reduction of MYocardial Damage during
Angioplasty) at Campus Bio-Medico University:
rationale, results and future horizons. Fundam. Clin.
Pharmacol. 2007 (Suppl. 2): 41-3.
- Patti G., Chello M., Candura D., Pasceri V.
Fibrillation in Patients Undergoing Cardiac
Surgery: Results of the ARMYDA-3 Randomized
Trial of Atorvastatin for Reduction of Postoperative
Atrial. Circulation. 2006; 114: 1455-61.
- Fang W.T., Li H.J., Zhang^ W., Jiang S. Efficacy of
statins for primary prevention in people at low cardiovascular
risk: a meta-analysis. CMAJ. 2011; 183
(16): E1189-202.
- Daskalopoulou S.S., Delaney J.A., Filion K.B.,
Brophy J.M., Mayo N.E., Suissa S. Discontinuation
of statin therapy following an acute myocardial
infarction: a population-based study. Eur. Heart J.
2008; 29: 2083-91.
- Swedberg K., Komajda M., Bohm M., Borer J.S.,
Ford I., Dubost-Brama A. et al. Ivabradine and outcomes
in chronic heart failure (SHIFT): a randomised
placebo-controlled study. Lancet; 376:
875-85.
- Lopez-Bescos L. Long-term safety and antianginal
efficacy of the If current inhibitor ivabradin in
patients with chronic stable angina. Eur. Heart J.
2004; 25. Abstract: 876.
- Rusyllo W., Ford I., Tendera M. et al. Antianginal
and antiischemic effects of If current inhibitor
ivabradin compared to amlodipine as monoterapy
in patients with chronic stable angina. Eur. Heart J.
2004; 25: 2529-36. Abstract: 878.
- Tardif J.C., Ford I., Tendera M., Bourassa M.G.,
Fox K. On behalf of the INITIATIV Study Investigator
Group. Efficacy of ivabradin, a new selective If
inhibitor, compared with atenolol in with chronic
stable angina. Eur. Heart J. 2005; 26: 2529-36.
- Nash D.N., Nash S.D. Ranolazine for chronic stable
angina. Lancet. 2008; 372: 1335-41.
- Wilson S.R., Scirica B.M., Braunwald E., Murphy
S.A., Karwatowska-Prokopczuk E., Buros J.L.
еt al. Efficacy of ranolazine in patients with chronic
angina observations from the randomized, doubleblind,
placebo-controlled MERLIN-TIMI
(Metabolic Efficiency with Ranolazine for Less
Ischemia in Non-ST-Segment Elevation Acute
Coronary Syndromes) 36 Trial. J. Am. Coll. Cardiol.
2009; 53: 1510-6.
- Gapponi A., Pizarro R., Harrison J. Trimetazidine
for stable angina. Cochrane Database Syst. Rev
2005: CD003614.
